Episode Details

Summit Therapeutics ivonescimab, a potential Keytruda rival, has seen its stock soar due to recent U.S. FDA filing for non-small cell lung cancer treatment. Axsome Therapeutics and Madrigal Pharmaceuticals also shine with promising drugs for depression, narcolepsy, and liver diseases, offering big long-term rewards despite risks from trial setbacks or regulatory hurdles.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6b5fb8ba3a4ef498